Aspen RxHealth Raises $23M Series B Funding Round Led by Bessemer Venture Partners

Aspen RxHealth, developer of a first-of-its-kind clinical pharmacy model developed by pharmacists for pharmacists that delivers value for health plans and risk-bearing providers, today announced the closure of a $23 million Series B funding round led by Bessemer Venture Partners, with participation from other strategic investors including McKesson Ventures, Novartis, and Takeda Digital Ventures. Previous investors Humana and Flare Capital Partners also participated.

The funding will help Aspen RxHealth capitalize on the demand for its highly diverse community of pharmacists and poise the company for successful entrance into new markets.

“With a strong bench of investors and strategic partners supporting our vision of developing a new clinical pharmacy services model to deliver tangible value to health plans and risk-bearing providers, we are prepared for our next stage of growth,” said Aspen RxHealth CEO David Medvedeff. “This capital will help us deliver on our promise to create a true marketplace for pharmacists, rapidly scale our business at a time when pharmacy is ripe for disruption, and aggressively pursue newer, broader markets such as specialty pharmacy support and medication reconciliation.”

Aspen RxHealth intelligently matches pharmacists with patients based on often-overlooked social and clinical factors to enrich the patient-pharmacist experience and driver better outcomes for health plans and other risk-bearing providers. Aspen RxHealth has a community of more than 5,000 pharmacists—the largest in the nation—who empower patients with the information and action plans they need to achieve optimal health outcomes.

Read the original press release here.